Advicenne Secures Financing to Q2 2027 with New Bond Issue

Advicenne, a pharmaceutical firm focused on rare kidney diseases, has gained financial stability until the second quarter of 2027 through a bond financing deal worth up to €3.8 million. Key participants include Cemag Invest, Didier Laurens, Europe Offering, and L1 Capital. The initial funding of €1.4 million is immediately available, enabling Advicenne to advance the FDA registration of ADV7103 in the USA.

This financing enables Advicenne to continue its strategic plans amid ongoing safeguard proceedings. Additionally, it facilitates the company's financial restructuring while maintaining operational flexibility. The bond offering consists of a first tranche of straight bonds and a second tranche of convertible bonds. These arrangements are projected to cover operational expenses and support Advicenne's market entry efforts for ADV7103 in the United States by September 2026.